Below is the timeline since i last posted 8 months ago..
Have to start digging again to make updates since i havent been paying attention.
Maybe biotech winter is finally over and time to pay attention again.
It seems like there have been lots of changes and delays in timeline ( no surprise )
What is happening to GILD CART and CNS programs?- seems i have to start digging though the posts :)
SGMO event timeline update - replying to my timeline if you want to see changes.
Although all events are important for the company, I will highlight the ones I feel will have the most effect on share price ( not coincidentally its human trial data )
Where SGMO is now in trials:
Hemo A- Phase 3 started dosing 3q 2020- clinical hold 4q 2021- > 50% dosed
Fabrys- phase 1 dosing started 3q 2020- dosed 3 cohorts- 5 patients total
Beta Thal- phase 1 -dosed 5 patients phase 1- stopped dosing
Sickle cell- phase 1/2- 4 patients dosed
TxCell T reg for renal transplant- enrolled 1/ dose 1h 2022?
MPS II -dosed to cohort 3 multiple patients- - reboot possible
Fabry- data in phase 1 trial
GILD- CART IND
IND CNS Tau with Biogen
CART-Reg data in renal transplant patients
Sanofi- sickle data-
Hemo A Pfizer updated phase 3 data
Fabry- renal biopsy data cohort 3
Hemo A Pfizer full phase 3 data
Fabry 1 year extended cohort 3 data
Hemo A FDA accelerated filing - Pfizer
CART-Reg IND ( MS vs IBD)
Dose CNS Tau with Biogen
CNS Parkinson's IND with Biogen
CNS Autism IND with Novartis
GILD 2nd CART IND
Sanofi- sickle data
Launch Hemo A commercially *
Fabry file for FDA approval and launch